Sequenom

This article may contain citations that do not verify the text. Please check for citation inaccuracies. (October 2011) (Learn how and when to remove this message)

Sequenom, Inc.

Company type	Subsidiary
Traded as	NYSE: SQNM (2000–2016)
Industry	Biotechnology
Founded	1 January 1994
Headquarters	San Diego, California , US
Key people	Dirk van den Boom (CEO)
Products	MaterniT21 PLUS, MaterniT GENOME, VisibiliT, HerediT CF, HerediT UNIVERSAL, NextView, SensiGene RHD
Services	Non-Invasive Prenatal Testing (NIPT), Carrier Screening
Parent	LabCorp (2016–present)
Website	www.sequenom.com

Sequenom, Inc. is an American company based in San Diego, California. It develops enabling molecular technologies, and highly sensitive laboratory genetic tests for NIPT. Sequenom's wholly owned subsidiary, Sequenom Center for Molecular Medicine (SCMM), offers multiple clinical molecular genetics tests to patients, including MaterniT21, plus a noninvasive prenatal test for trisomy 21, trisomy 18, and trisomy 13, and the SensiGene RHD Fetal RHD genotyping test.

The company went public via an initial public offering in 2000.^[1] In June 2014 the company sold its biosciences unit to Agena Bioscience for up to $35.8 million.^[2] In July 2016, it was announced that diagnostic and testing giant LabCorp will acquire Sequenom, paying $2.40 for every outstanding share of Sequenom stock. The acquisition was completed in September 2016.^[3]